All In Biotech

BLA 761109 · Eli Lilly and CO

Lyumjev

Insulin Lispro-Aabc · Injection · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Oct 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 15, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

331

68 Phase 3, 9 recruiting

FAERS reports

2,106

454 serious, 35 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

LYUMJEV ® is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. LYUMJEV ® is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: The primary activity of LYUMJEV is the regulation of glucose metabolism. Insulins, including insulin lispro-aabc, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • LYUMJEV · INSULIN LISPRO-AABC 200UNITS/ML(U-200) · INJECTABLE, INJECTION · Prescription
  • LYUMJEV · INSULIN LISPRO-AABC 100UNITS/ML(U-100) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Lispro" as an intervention, any sponsor and status, largest first.

All 331 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased566
  • infusion site pain266
  • drug ineffective224
  • injection site pain224
  • wrong technique in product usage process160
  • incorrect dose administered148
  • blood glucose decreased103
  • product dose omission issue71
  • visual impairment63
  • haemorrhage57
  • blood glucose abnormal56
  • accidental underdose55

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20181
20192
202078
2021372
2022393
2023340
2024342
2025383
2026194

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lyumjev (Insulin Lispro-Aabc)

2024 spending

$19.9M

Beneficiaries

5,449

17,978 claims

Per beneficiary

$3,657

$24.77 per unit

View as table
YearSpending
2020$193,210
2021$3,050,167
2022$8,211,586
2023$14,719,969
2024$19,927,368

Part B: Lyumjev (Insulin Lispro-Aabc) · HCPCS J1813

2024 spending

$2.0M

Beneficiaries

480

1,433 claims

Per beneficiary

$4,178

2024 ASP limit $15.58 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$650,022
2024$2,005,639

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 355 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.